Vorinostat in Patients With Primary Cutaneous T-Cell Lymphoma

This study is currently recruiting participants.
Verified September 2013 by University of Washington
Sponsor:
Collaborator:
Information provided by (Responsible Party):
University of Washington
ClinicalTrials.gov Identifier:
NCT00958074
First received: August 10, 2009
Last updated: September 20, 2013
Last verified: September 2013

August 10, 2009
September 20, 2013
July 2009
September 2016   (final data collection date for primary outcome measure)
Objective response [ Time Frame: After at least 28 days ] [ Designated as safety issue: No ]
Defined as either no evidence of clinical disease or marked improvement (>= 50%) decrease in the modified Severity-Weighted Assessment Tool (mSWAT) skin assessment score compared to baseline.
Objective response [ Time Frame: Baseline and at least 28 days ] [ Designated as safety issue: No ]
Complete list of historical versions of study NCT00958074 on ClinicalTrials.gov Archive Site
  • Objective response rate of extracutaneous manifestations of CTCL (lymph node enlargement, Sezary cells in peripheral blood); [ Time Frame: Up to 30 days post-treatment ] [ Designated as safety issue: No ]
    Assessed by changes in the sum of the products in the greatest diameters of enlarged lymph nodes by serial computed tomography (CT) or positron emission tomography (PET)/CT scans.
  • Safety and tolerability of dose-adjusted vorinostat [ Time Frame: Up to 30 days post-treatment ] [ Designated as safety issue: Yes ]
    Toxicities will be graded in severity according to the guidelines outlined in the National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 3.0.
  • Changes in sezary cell count measured by serial flow cytometry measurements [ Time Frame: Baseline to 30 days post-treatment ] [ Designated as safety issue: No ]
  • Changes in the Physicians serial assessment of erythroderma score [ Time Frame: Baseline to 30 days post-treatment ] [ Designated as safety issue: No ]
  • Lymph enlargement [ Time Frame: Baseline and periodically during treatment with CT scans every 12 weeks ] [ Designated as safety issue: No ]
  • Changes in the Physicians serial assessment of erythroderma score [ Time Frame: Baseline and periodically during treatment, every 14 days ] [ Designated as safety issue: No ]
  • Sezary cell count (patients with Sezary cells in peripheral blood only) by flow cytometry [ Time Frame: Baseline and periodically during treatment; at least every 28 days ] [ Designated as safety issue: No ]
Not Provided
Not Provided
 
Vorinostat in Patients With Primary Cutaneous T-Cell Lymphoma
A Phase II Prospective Non-Randomized Two-Arm Clinical Trial of Dose-Adjusted Schedule of Vorinostat in Patients With Primary Cutaneous T-Cell Lymphoma (CTCL) Who Did Not Receive Prior Systemic Therapy or Have Been Treated With Single Agent Targretin

This phase II trial studies the side effects and how well vorinostat works in treating patients with primary cutaneous T-cell lymphoma. Vorinostat may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth

PRIMARY OBJECTIVES:

I. To determine the objective response rate to treatment with dose-adjusted Vorinostat schedule in subjects with cutaneous T-cell lymphoma (CTCL) who did not receive prior systematic therapy or have been treated with single agent targretin (bexarotene).

SECONDARY OBJECTIVES:

I. To determine the safety and tolerability of dose-adjusted Vorinostat schedule when administered to patients with primary cutaneous T-cell lymphoma who did not receive prior systematic therapy or have been treated with single agent targretin.

II. To determine the time to objective response in subjects with CTCL treated with dose-adjusted schedule of Vorinostat as primary therapy.

III To determine the duration of objective response in subjects with CTCL.

IV. To determine the time to loss of objective response.

V. To determine the objective response rate of extracutaneous manifestations of CTCL (lymph node enlargement, Sezary cells in peripheral blood).

VI. To compare the efficacy, toxicity and tolerability of dose-adjusted schedule to currently recommended flat dose of Vorinostat in subjects with CTCL.

OUTLINE: Patients are assigned to 1 of 2 treatment arms according to age (< 65 vs >= 65 years old).

COHORT I (>= 65 years old): Patients receive 200 mg vorinostat orally (PO) once daily (QD) on days 1-28. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.

COHORT II (< 65 years old): Patients receive 400 mg vorinostat PO QD on days 1-28. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up for at least 30 days.

Interventional
Phase 2
Allocation: Non-Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
  • Stage I Cutaneous T-cell Non-Hodgkin Lymphoma
  • Stage I Mycosis Fungoides/Sezary Syndrome
  • Stage II Cutaneous T-cell Non-Hodgkin Lymphoma
  • Stage II Mycosis Fungoides/Sezary Syndrome
  • Stage III Cutaneous T-cell Non-Hodgkin Lymphoma
  • Stage III Mycosis Fungoides/Sezary Syndrome
  • Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma
  • Stage IV Mycosis Fungoides/Sezary Syndrome
  • Drug: vorinostat
    Given PO
    Other Names:
    • L-001079038
    • SAHA
    • suberoylanilide hydroxamic acid
    • Zolinza
  • Other: flow cytometry
    correlative study
  • Other: laboratory biomarker analysis
    correlative study
  • Experimental: Cohort I (greater than or equal to 65 years old)
    Patients receive 200 mg vorinostat PO QD on days 1-28. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.
    Interventions:
    • Drug: vorinostat
    • Other: flow cytometry
    • Other: laboratory biomarker analysis
  • Experimental: Cohort II (less than 65 years old)
    Patients receive 400 mg vorinostat PO QD on days 1-28. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.
    Interventions:
    • Drug: vorinostat
    • Other: flow cytometry
    • Other: laboratory biomarker analysis
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
40
Not Provided
September 2016   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Males or non-pregnant females
  • Histologically confirmed diagnosis of CTCL, including mycosis fungoides and/or Sezary syndrome
  • Documentation of diagnosis by histologic examination should be available
  • Subjects with CTCL stages IB, IIA, IIB, III, or IVA who have not received any prior systemic therapies
  • Anticipated life expectancy greater than 6 months
  • Performance status 0, 1, or 2 by Eastern Cooperative Oncology Group (ECOG) criteria
  • Written informed consent to participate in the study
  • Absolute neutrophil count (ANC) >= 1,000/mcL
  • Platelets >= 75,000/mcL
  • Hemoglobin >= 9 g/dL
  • Prothrombin time or international normalized ratio (INR) =< 1.5 x upper limit of normal (ULN) unless receiving therapeutic anticoagulation
  • Partial thromboplastin time (PTT) =< 1.2 times the ULN unless the patient is receiving therapeutic anticoagulation
  • Serum creatinine =< 1.5 X ULN OR calculated creatinine clearance >= 60 mL/min for patients with creatinine levels > 1.5 X institutional ULN; creatinine clearance should be calculated per institutional standard
  • Serum total bilirubin =< 2 X ULN
  • Aspartate aminotransferase (AST) (serum glutamic oxaloacetic aminotransaminase [SGOT]) and alanine aminotransferase (ALT) (serum glutamic pyruvic aminotransaminase [SGPT]) =< 3.0 X ULN
  • Alkaline Phosphatase (liver fraction) =< 3.0 X ULN

Exclusion Criteria:

  • Proven or suspected extracutaneous visceral CTCL involvement (M1) (CTCL stage IVB)
  • Presence of lymphadenopathy is permitted
  • ECOG performance status > 2
  • Concomitant use of any anti-cancer therapy or immune modifier
  • Concomitant use of any investigational agent or device
  • Concomitant therapy with any other anti-CTCL therapy, or radiation therapy (topical corticosteroids or low dose oral corticosteroids [=< 10 mg/day prednisone or equivalent] will not be excluded, but if used, the dose and schedule must be stable during the two weeks immediately prior to study entry)
  • Use of any previous systemic therapy (except single agent targretin), total skin electron beam (TSEB) therapy or extracorporeal photopheresis
  • Evidence of clinically significant (uncontrolled) hypo- or hyperthyroidism
  • Poorly controlled diabetes mellitus as evidenced by hemoglobin (Hgb)A1c > 6.5 mg/dl
  • Recent (in the past 6 months) medically significant cardiac event (i.e. myocardial infarction, cardiac surgery)
  • Presence of congestive heart failure (New York Heart Association [NYHA] class IV) or angina (NYHA class IV) or presence of a medically significant arrhythmia
  • Congenital long QT syndrome
  • Corrected QT interval > 480 msec on screening electrocardiogram (ECG)
  • Presence of uncontrolled hypertension manifested by systolic blood pressure >= 180 mmHg and/or diastolic blood pressure >= 100 mmHg
  • Documented current active infection with human immunodeficiency virus (HIV), Hepatitis B, Hepatitis C, and/or cytomegalovirus (CMV)
  • Presence of uncontrolled bacterial or viral infection (subject may be receiving chronic antimicrobial therapy)
  • History of culture-documented bacteremia in the previous 2 weeks
  • Concurrent therapy with any histone deacetylase (HDAC)-like compound; patients treated with valproic acid for epilepsy may enroll after a 30 day washout period
  • Recent change (in the past 2 weeks) in the doses or regimens of medication used for any chronic non-oncologic conditions for reasons of worsening of chronic illness (change in doses of chronic medications associated with improvement in a chronic illness are not exclusion criteria)
  • Presence of any acute or chronic non-oncologic disease which, in the opinion of the investigator, is medically uncontrolled
  • History of a prior malignancy with the exception of cervical intraepithelial neoplasia; non-melanoma skin cancer; adequately treated localized prostate carcinoma with prostate specific antigen (PSA) < 1.0; or who has undergone potentially curative therapy with no evidence of that disease for five years, and/or who is deemed at low risk for recurrence (< 30% probability) by his/her treating physician
  • Patient with a "currently active" second malignancy, other than nonmelanoma skin cancer and carcinoma in situ of the cervix, should not be enrolled
  • Any significant medical or psychiatric condition that, in the opinion of the investigator, might prevent the subject from complying with all required study procedures
  • Women of childbearing potential must have a pregnancy test within 28 days prior to registration, and must use an adequate method of contraception to avoid pregnancy throughout the study and for a period of at least 3 months after the study
  • Females of childbearing potential and sexually active males, if indicated, must be willing and able to use two methods of contraception that are adequate to prevent or minimize risk of pregnancy for the duration of the study; one of which must be a barrier method
  • Patient has symptomatic ascites or pleural effusion (a patient who is clinically stable following treatment for these conditions is eligible)
  • Patient has had allogeneic transplant
  • Patient has a history of a gastrointestinal surgery or other procedures that might, in the opinion of the investigator, interfere with the absorption or swallowing of the study drugs
Both
18 Years and older
No
Not Provided
United States
 
NCT00958074
6914, NCI-2009-01231
No
University of Washington
University of Washington
National Cancer Institute (NCI)
Principal Investigator: Andrei Shustov Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
University of Washington
September 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP